Rectiv is a drug owned by Abbvie Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 21, 2014. Details of Rectiv's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7189761 | Nitric oxide donor composition and method for treatment of anal disorders |
May, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rectiv's patents.
Latest Legal Activities on Rectiv's Patents
Given below is the list of recent legal activities going on the following patents of Rectiv.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 15 Apr, 2019 | US7189761 |
| Maintenance Fee Reminder Mailed Critical | 29 Oct, 2018 | US7189761 |
| Recordation of Patent Grant Mailed Critical | 13 Mar, 2007 | US7189761 |
| Patent Issue Date Used in PTA Calculation Critical | 13 Mar, 2007 | US7189761 |
| Issue Notification Mailed Critical | 21 Feb, 2007 | US7189761 |
| Application Is Considered Ready for Issue Critical | 30 Jan, 2007 | US7189761 |
| Dispatch to FDC | 30 Jan, 2007 | US7189761 |
| Issue Fee Payment Verified Critical | 26 Jan, 2007 | US7189761 |
| Issue Fee Payment Received Critical | 26 Jan, 2007 | US7189761 |
| Mail Notice of Allowance Critical | 30 Oct, 2006 | US7189761 |
FDA has granted several exclusivities to Rectiv. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Rectiv, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Rectiv.
Exclusivity Information
Rectiv holds 1 exclusivities. All of its exclusivities have expired in 2014. Details of Rectiv's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 21, 2014 |
US patents provide insights into the exclusivity only within the United States, but Rectiv is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Rectiv's family patents as well as insights into ongoing legal events on those patents.
Rectiv's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Rectiv's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 21, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Rectiv Generic API suppliers:
Nitroglycerin is the generic name for the brand Rectiv. 26 different companies have already filed for the generic of Rectiv, with Mylan Technologies having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Rectiv's generic
Alternative Brands for Rectiv
Rectiv which is used for managing moderate to severe pain associated with chronic anal fissure., has several other brand drugs using the same active ingredient (Nitroglycerin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Evus |
| ||
| Pohl Boskamp |
| ||
| Viatris |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Nitroglycerin, Rectiv's active ingredient. Check the complete list of approved generic manufacturers for Rectiv
About Rectiv
Rectiv is a drug owned by Abbvie Inc. It is used for managing moderate to severe pain associated with chronic anal fissure. Rectiv uses Nitroglycerin as an active ingredient. Rectiv was launched by Abbvie in 2011.
Approval Date:
Rectiv was approved by FDA for market use on 21 June, 2011.
Active Ingredient:
Rectiv uses Nitroglycerin as the active ingredient. Check out other Drugs and Companies using Nitroglycerin ingredient
Treatment:
Rectiv is used for managing moderate to severe pain associated with chronic anal fissure.
Dosage:
Rectiv is available in ointment form for intra-anal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.4% | OINTMENT | Prescription | INTRA-ANAL |